Shanrong Biotechnology Corp.
SRBT
$0.13
-$0.03-19.03%
OTC PK
| 12/31/2009 | 09/30/2009 | 06/30/2009 | 03/31/2009 | 12/31/2008 | |
|---|---|---|---|---|---|
| Revenue | -57.40% | 0.24% | 198.48% | 412.63% | 20.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.40% | 0.24% | 198.48% | 412.63% | 20.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -57.40% | 0.24% | 198.48% | 412.63% | 20.33% |
| SG&A Expenses | 266.74% | -117.41% | 77.24% | 42.90% | 10.44% |
| Depreciation & Amortization | 0.00% | 898.88% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 264.59% | -102.98% | 76.08% | 42.42% | 10.35% |
| Operating Income | -360.77% | 129.13% | 0.54% | -0.45% | -7.69% |
| Income Before Tax | -295.70% | 134.62% | -6.52% | -0.78% | -21.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -295.70% | 134.62% | -6.52% | -0.78% | -21.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -295.70% | 134.62% | -6.52% | -0.78% | -21.57% |
| EBIT | -360.77% | 129.13% | 0.54% | -0.45% | -7.69% |
| EBITDA | -364.53% | 131.47% | 0.56% | -0.45% | -7.76% |
| EPS Basic | -1,157.39% | 107.72% | 76.19% | -0.80% | 48.75% |
| Normalized Basic EPS | -1,157.37% | 107.72% | 76.19% | -0.80% | 48.75% |
| EPS Diluted | -1,029.60% | 107.72% | 76.19% | -0.80% | 41.69% |
| Normalized Diluted EPS | -1,157.37% | 107.72% | 76.19% | -0.80% | 48.75% |
| Average Basic Shares Outstanding | -68.54% | 348.46% | 347.35% | 0.00% | 137.23% |
| Average Diluted Shares Outstanding | -68.54% | 348.46% | 347.35% | 0.00% | 137.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |